Literature DB >> 2307732

Testosterone replacement therapy and sleep-related erections in hypogonadal men.

G R Cunningham1, M Hirshkowitz, S G Korenman, I Karacan.   

Abstract

Hypogonadal men usually have diminished libido and erectile dysfunction, and testosterone replacement therapy in these men increases sexual activity, erotic thoughts, and self-reported nocturnal erections. The polygraphic assessment of nocturnal penile tumescence (NPT) provides an objective index of erectile capability and is useful for differentiating psychogenic from organic erectile dysfunction. In this study we evaluated NPT in six hypogonadal adult men during and after termination of androgen therapy. Multinight sleep studies were conducted within 1 week and 7-8 weeks after each man received 20 mg testosterone cypionate, im. The mean serum testosterone level 4-7 days after testosterone injection was 35.9 +/- 3.4 (+/- SE) nmol/L, and it fell to 2.3 +/- 0.9 nmol/L after 7-8 weeks. Significant declines (P less than 0.05) in the number of NPT episodes (3.7 to 2.0), maximum penile circumference increase (24 to 13 mm), and total tumescence time (107 to 55 min) accompanied the fall in the serum testosterone level. No androgen-related changes in the amount or integrity of rapid eye movement sleep were found. Finally, the mean penile rigidity (buckling pressure) decreased from 770 +/- 98 to 590 +/- 81 g (P less than 0.05). Comparison of these results to those in normal men revealed that none of these men met all diagnostic criteria for organic impotence, even 7-8 weeks after discontinuation of testosterone administration. While men with androgen deficiency may have normal NPT, sleep-related erections increase in response to testosterone administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2307732     DOI: 10.1210/jcem-70-3-792

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Sleep-related erections: neural mechanisms and clinical significance.

Authors:  Markus H Schmidt; Helmut S Schmidt
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

2.  Testosterone for erectile failure.

Authors:  T Mulligan; B Schmitt
Journal:  J Gen Intern Med       Date:  1993-09       Impact factor: 5.128

3.  Hormones and nocturnal penile tumescence in healthy aging men.

Authors:  R C Schiavi; D White; J Mandeli; P Schreiner-Engel
Journal:  Arch Sex Behav       Date:  1993-06

Review 4.  Updates on the relation of weight excess and reproductive function in men: sleep apnea as a new area of interest.

Authors:  Ahmad O Hammoud; Douglas T Carrell; Mark Gibson; C Matthew Peterson; A Wayne Meikle
Journal:  Asian J Androl       Date:  2011-12-05       Impact factor: 3.285

5.  Priapism induced by boceprevir-CYP3A4 inhibition and α-adrenergic blockade: case report.

Authors:  Kyle P Hammond; Craig Nielsen; Sunny A Linnebur; Jacob A Langness; Graham Ray; Paul Maroni; Jennifer J Kiser
Journal:  Clin Infect Dis       Date:  2013-10-02       Impact factor: 9.079

Review 6.  Effect of androgens on penile tissue.

Authors:  Ronald W Lewis; Thomas M Mills
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 7.  The Role of Testosterone Therapy in the Setting of Prostate Cancer.

Authors:  Katherine M Rodriguez; Alexander W Pastuszak; Mohit Khera
Journal:  Curr Urol Rep       Date:  2018-06-30       Impact factor: 3.092

8.  Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.

Authors:  Tony Chen; Shufeng Li; Michael L Eisenberg
Journal:  J Sex Med       Date:  2021-07-22       Impact factor: 3.937

Review 9.  If I could just stop loving you: anti-love biotechnology and the ethics of a chemical breakup.

Authors:  Brian D Earp; Olga A Wudarczyk; Anders Sandberg; Julian Savulescu
Journal:  Am J Bioeth       Date:  2013       Impact factor: 11.229

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.